# CVR Partners, LP: overview

UAN · NYSE · CIK 1425292 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/uan.md) · [Financials](/companies/uan/financials.md) · [Filings](/companies/uan/filings.md) · [Insiders](/companies/uan/insiders.md)

Latest reported revenue: [$202.2m](/filings/0001425292-26-000031.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001425292-26-000031).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [125](/filings/0001425292-25-000030.md) | [140 d](/filings/0001425292-26-000011.md) | [143](/filings/0001425292-26-000022.md) | [169](/filings/0001425292-26-000031.md) | [164](/filings/0001425292-25-000030.md) | [131 d](/filings/0001425292-26-000011.md) | [180](/filings/0001425292-26-000022.md) | [202](/filings/0001425292-26-000031.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [8.8%](/filings/0001425292-25-000030.md) | [18.4% d](/filings/0001425292-26-000011.md) | [24.2%](/filings/0001425292-26-000022.md) | [27.5%](/filings/0001425292-26-000031.md) | [31.0%](/filings/0001425292-25-000030.md) | [(2.2%) d](/filings/0001425292-26-000011.md) | [32.0%](/filings/0001425292-26-000022.md) | [41.9%](/filings/0001425292-26-000031.md) |
| Net margin | % | [3.0%](/filings/0001425292-25-000030.md) | [13.1% d](/filings/0001425292-26-000011.md) | [19.0%](/filings/0001425292-26-000031.md) | [23.0%](/filings/0001425292-26-000031.md) | [26.3%](/filings/0001425292-25-000030.md) | [(7.8%) d](/filings/0001425292-26-000011.md) | [27.7%](/filings/0001425292-26-000031.md) | [38.3%](/filings/0001425292-26-000031.md) |
| Diluted EPS | $ per share | [0.36](/filings/0001425292-25-000030.md) | not reported | [2.56](/filings/0001425292-26-000022.md) | [3.67](/filings/0001425292-26-000031.md) | [4.08](/filings/0001425292-25-000030.md) | not reported | [4.72](/filings/0001425292-26-000022.md) | [7.33](/filings/0001425292-26-000031.md) |
| Free cash flow | $m | [82.3 d](/filings/0001425292-25-000030.md) | [(5.6) d](/filings/0001425292-26-000011.md) | [45.5](/filings/0001425292-26-000022.md) | [18.4 d](/filings/0001425292-26-000031.md) | [80.1 d](/filings/0001425292-25-000030.md) | [(45.2) d](/filings/0001425292-26-000011.md) | [58.7](/filings/0001425292-26-000022.md) | [50.9 d](/filings/0001425292-26-000031.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [533](/filings/0001425292-24-000004.md) | [836](/filings/0001425292-25-000004.md) | [681](/filings/0001425292-26-000011.md) | [525](/filings/0001425292-26-000011.md) | [606](/filings/0001425292-26-000011.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [25.3%](/filings/0001425292-24-000004.md) | [38.3%](/filings/0001425292-25-000004.md) | [29.6%](/filings/0001425292-26-000011.md) | [17.2%](/filings/0001425292-26-000011.md) | [21.2%](/filings/0001425292-26-000011.md) |
| Net margin | % | [14.7%](/filings/0001425292-24-000004.md) | [34.3%](/filings/0001425292-25-000004.md) | [25.3%](/filings/0001425292-26-000011.md) | [11.6%](/filings/0001425292-26-000011.md) | [16.3%](/filings/0001425292-26-000011.md) |
| Diluted EPS | $ per share | [7.31](/filings/0001425292-24-000004.md) | [27.07](/filings/0001425292-25-000004.md) | [16.31](/filings/0001425292-26-000011.md) | [5.76](/filings/0001425292-26-000011.md) | [9.33](/filings/0001425292-26-000011.md) |
| Free cash flow | $m | [168](/filings/0001425292-24-000004.md) | [257](/filings/0001425292-25-000004.md) | [219](/filings/0001425292-26-000011.md) | [113](/filings/0001425292-26-000011.md) | [98.8](/filings/0001425292-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/uan/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2017-12-07 | [Blackstone Holdings I L.P.](/insiders/1464694.md) | 10% owner | Sale (S) | 153,184 | $3.0001 | $459.6k | [Form 4](/filings/0000899243-17-028447.md) |
| 2017-12-07 | [Blackstone Holdings I L.P.](/insiders/1464694.md) | 10% owner | Sale (S) | 85,424 | $3.0001 | $256.3k | [Form 4](/filings/0000899243-17-028447.md) |
| 2017-12-07 | [Blackstone Holdings I L.P.](/insiders/1464694.md) | 10% owner | Sale (S) | 219,886 | $3.0001 | $659.7k | [Form 4](/filings/0000899243-17-028447.md) |
| 2017-12-07 | [Blackstone Holdings I L.P.](/insiders/1464694.md) | 10% owner | Sale (S) | 85,485 | $3.0001 | $256.5k | [Form 4](/filings/0000899243-17-028447.md) |
| 2017-12-07 | [Blackstone Holdings I L.P.](/insiders/1464694.md) | 10% owner | Sale (S) | 619,729 | $3.0001 | $1.9m | [Form 4](/filings/0000899243-17-028447.md) |
| 2017-12-07 | [Blackstone Holdings I L.P.](/insiders/1464694.md) | 10% owner | Sale (S) | 736,292 | $3.0001 | $2.2m | [Form 4](/filings/0000899243-17-028447.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ICAHN CARL C](/funds/921669.md) | 2026-06-30 | $464.2m | 4,164,274 |  | Unchanged |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $48.9m | 438,977 |  | Reduced −94,378 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $21.1m | 187,535 |  | Added +63,465 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $19.4m | 174,400 | Call | Added +22,800 |
| [MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.](/funds/1705339.md) | 2026-06-30 | $15.9m | 142,552 |  | Added +5,530 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $15.4m | 138,304 |  | Reduced −33,713 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $13.2m | 118,400 | Put | Added +84,100 |
| [ING GROEP NV](/funds/1039765.md) | 2026-06-30 | $9.3m | 83,100 |  | Added +24,000 |
| [Oxbow Advisors, LLC](/funds/1564770.md) | 2026-06-30 | $7.8m | 70,310 |  | Added +542 |
| [De Lisle Partners LLP](/funds/2011184.md) | 2026-06-30 | $6.1m | 54,233 |  | Added +600 |

## Recent filings

[All 532 filings](/companies/uan/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-29 | 12:23 ET | [10-Q](/filings/0001425292-26-000031.md) | Quarterly report, period 2026-06-30 | 0001425292-26-000031 |
| 2026-07-29 | 12:20 ET | [8-K](/filings/0001425292-26-000030.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001425292-26-000030 |
| 2026-06-23 | 18:04 ET | [8-K](/filings/0001425292-26-000025.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001425292-26-000025 |
| 2026-04-29 | 16:31 ET | [10-Q](/filings/0001425292-26-000022.md) | Quarterly report, period 2026-03-31 | 0001425292-26-000022 |
| 2026-04-29 | 16:27 ET | [8-K](/filings/0001425292-26-000021.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001425292-26-000021 |
| 2026-03-18 | 16:17 ET | [8-K](/filings/0001425292-26-000018.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws | 0001425292-26-000018 |
| 2026-03-03 | 17:28 ET | [8-K](/filings/0001425292-26-000014.md) | 3.01 Delisting notice | 0001425292-26-000014 |
| 2026-02-18 | 16:33 ET | [10-K](/filings/0001425292-26-000011.md) | Annual report, period 2025-12-31 | 0001425292-26-000011 |
| 2026-02-18 | 16:29 ET | [8-K](/filings/0001425292-26-000010.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001425292-26-000010 |
| 2026-01-26 | 07:25 ET | [8-K](/filings/0001425292-26-000007.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001425292-26-000007 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001425292-26-000011.md), filed Feb 18, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2a62ca2e-fb27-4be3-84a5-703de9541e42)

## About the filer

- CIK: 1425292
- Tickers: UAN
- Exchange: NYSE
- SIC code: 2870 Agricultural Chemicals
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.